Assembly Biosciences (ASMB) news
Recent news
ASMI shares rise 1.7%, top of AEX
AInvest Wire · 1d agoAssembly Biosciences - Assembly Bio expects cash runway into 2029
Assembly Biosciences, Inc. (Nasdaq: ASMB) reported a second-quarter 2026 cash runway extending into 2029, supported by a $115 million gross financing and a $75 million payment from its collaboration with Gilead Sciences, Inc. expected in Q4 2026. As of June 30, 2026, the company held $320.4 million…
AInvest Wire · Sep 8, 2026Assembly Biosciences - GS-1179 expected to advance into phase 2 trial for genital herpes by end of 2026
AInvest Wire · Sep 8, 2026Assembly Biosciences - Assembly Bio eligible for up to $280 mln in milestones and royalties outside U.S.
AInvest Wire · Sep 8, 2026Assembly Biosciences exercises U.S. profit-share option with Gilead for HSV helicase-primase inhibitor program
Gilead Sciences has exercised its option to license Assembly Biosciences’ herpes simplex virus (HSV) helicase-primase inhibitor programs, including ABI-1179 and ABI-5366, for the treatment of recurrent genital herpes. This marks the first step in advancing these programs under the ongoing…
AInvest Wire · Sep 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.